Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sunil Babu"'
Autor:
Vernon K. Sondak, Andrew Poklepovic, Nikhil I. Khushalani, Jason J. Luke, Sunil Babu, Sigrun Hallmeyer, Zeynep Eroglu, Mario R. Velasco, Emily F. Higgs, Bruce Brockstein, Daniel J Olson, Thomas Krausz, Madhuri Bajaj, Timothy Carll, Riyue Bao, Jose Lutzky, Theodore Karrison, Brian W. Labadie, Thomas F. Gajewski, Yuanyuan Zha
Publikováno v:
J Clin Oncol
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial anti-PD-1 and p
Autor:
Ang Li, Jason C. Chandler, Davey B. Daniel, Félix Couture, Sunil Babu, Vijay Gunuganti, Maen A. Hussein, Robert M. Jotte, Samer Kasbari, Michael McCleod, Edward B. Garon, Justin N. Baker, Nivedita Aanur, Lawrence H. Einhorn, Leora Horn, Ben C. Creelan, Petros Nikolinakos, George P. Keogh, David R. Spigel, Craig Reynolds, Natasha B. Leighl, David M. Waterhouse, George R. Blumenschein
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(33)
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-y
Autor:
Craig W. Reynolds, Paul Thurmes, Wen Hong Lin, Sunil Babu, Jin Zhu, David R. Spigel, Robert M. Jotte, David M. Waterhouse, Edward B. Garon, Jason C. Chandler, George R. Blumenschein, Alexander I. Spira
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(5)
Introduction Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is a first-line treatment for ALK translocation–positive advanced non–small cell lung cancer (NSCLC); however, patients eventually progress. Immunotherapies, including the pr
Autor:
Richard R. Furman, Bruno Moulin, Timothy H.J. Goodship, Sunil Babu, Maria Herthelius, Jens Nürnberger, Neil S. Sheerin, Petra Muus, C. Bedrosian, Rebecca Sberro-Soussan, C. Bingham, Christoph Licht, Yvon Lebranchu, Jan Menne, Christophe Mariat, B. Severino, Frank Eitner, Y. Delmas, Osama Gaber, T. Richard, David J. Cohen, Thorsten Feldkamp, Denis Fouque, Kenneth W. Douglas, Diana Karpman, Chantal Loirat, Maryvonne Hourmant, Masayo Ogawa, Antonella Trivelli, Giuseppe Remuzzi, Ch. Legendre, L.B. Zimmerhackl, Laurence Greenbaum
Publikováno v:
The New England Journal of Medicine, 368, 23, pp. 2169-81
New England Journal of Medicine; 368(23), pp 2169-2181 (2013)
The New England Journal of Medicine, 368, 2169-81
New England Journal of Medicine; 368(23), pp 2169-2181 (2013)
The New England Journal of Medicine, 368, 2169-81
Item does not contain fulltext BACKGROUND: Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hem